Page last updated: 2024-10-16

carnitine and Pain

carnitine has been researched along with Pain in 11 studies

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines."9.14Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009)
"Patients with cystic acne (CA) on Isotretinoin (Iso) therapy might present muscular symptoms as side effect of the drug."9.09L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. ( Georgala, C; Georgala, S; Michas, T; Schulpis, KH, 1999)
" The aim of the study was to investigate the effects of oral L-carnitine supplementation on pain (VAS scale), tenderness (pain thresholds) and CK release induced by a 20-min eccentric effort of the quadriceps muscle."9.08Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. ( Di Lisa, F; Dragani, L; Giamberardino, MA; Saggini, R; Valente, R; Vecchiet, L, 1996)
"Muscle cramps are side effects commonly associated with tyrosine kinase inhibitor (TKI) treatment."5.43[Efficacy of levocarnitine for tyrosine kinase inhibitor-induced painful muscle cramps in patients with chronic myelogenous leukemia]. ( Abe, T; Fujii, S; Hamaguchi, K; Horiguchi, H; Ito, R; Kato, J; Kuroda, H; Maeda, M; Nakamura, H; Sato, K; Shimoyama, S; Sugama, Y; Yamada, M; Yamauchi, N, 2016)
"To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines."5.14Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009)
"Patients with cystic acne (CA) on Isotretinoin (Iso) therapy might present muscular symptoms as side effect of the drug."5.09L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. ( Georgala, C; Georgala, S; Michas, T; Schulpis, KH, 1999)
" The aim of the study was to investigate the effects of oral L-carnitine supplementation on pain (VAS scale), tenderness (pain thresholds) and CK release induced by a 20-min eccentric effort of the quadriceps muscle."5.08Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. ( Di Lisa, F; Dragani, L; Giamberardino, MA; Saggini, R; Valente, R; Vecchiet, L, 1996)
"Many patients with chronic fatigue syndrome(CFS) fulfill the criteria of FMS and represent one end of a spectrum of presentation."2.40[Fibromyalgia syndrome]. ( Matsumoto, Y, 1999)
"Muscle cramps are side effects commonly associated with tyrosine kinase inhibitor (TKI) treatment."1.43[Efficacy of levocarnitine for tyrosine kinase inhibitor-induced painful muscle cramps in patients with chronic myelogenous leukemia]. ( Abe, T; Fujii, S; Hamaguchi, K; Horiguchi, H; Ito, R; Kato, J; Kuroda, H; Maeda, M; Nakamura, H; Sato, K; Shimoyama, S; Sugama, Y; Yamada, M; Yamauchi, N, 2016)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19902 (18.18)18.7374
1990's3 (27.27)18.2507
2000's5 (45.45)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yamada, M1
Kuroda, H1
Shimoyama, S1
Ito, R1
Sugama, Y1
Sato, K1
Yamauchi, N1
Horiguchi, H1
Nakamura, H1
Hamaguchi, K1
Abe, T1
Fujii, S1
Maeda, M1
Kato, J1
Milio, G1
Novo, G1
Genova, C1
Luigi Almasio, P1
Novo, S1
Pinto, A1
Boneh, A1
Baumgartner, M1
Hayman, M1
Peters, H1
Fietta, P1
Manganelli, P1
Spiering, BA1
Kraemer, WJ2
Vingren, JL1
Hatfield, DL1
Fragala, MS1
Ho, JY1
Maresh, CM1
Anderson, JM1
Volek, JS2
Giamberardino, MA1
Dragani, L1
Valente, R1
Di Lisa, F1
Saggini, R1
Vecchiet, L1
Matsumoto, Y1
Georgala, S1
Schulpis, KH1
Georgala, C1
Michas, T1
Rubin, MR1
Gómez, AL1
Ratamess, NA1
Gaynor, P1
Brand, G1
Bellmann, H1
Kothe, W1
Duck, HJ1
Rauchfuss, E1
Fleischmann, H1
Schönlebe, W1
Böhland, W1
Byrne, E1
Trounce, I1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172]Phase 4164 participants (Actual)Interventional2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Claudication Onset Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.065
Cilostazol + Placebo0.896

Change From Baseline in Claudication Onset Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.001
Cilostazol + Placebo0.815

Change From Baseline in Peak Walking Time (PWT) at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.241
Cilostazol + Placebo0.134

Change From Baseline in Peak Walking Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.267
Cilostazol + Placebo0.145

Change From Baseline in Peak Walking Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.166
Cilostazol + Placebo0.139

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine13.20
Cilostazol + Placebo6.57

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine12.98
Cilostazol + Placebo10.01

Reviews

1 review available for carnitine and Pain

ArticleYear
[Fibromyalgia syndrome].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:2

    Topics: Biomarkers; Carnitine; Diagnosis, Differential; Fatigue; Fatigue Syndrome, Chronic; Fibromyalgia; Hu

1999

Trials

5 trials available for carnitine and Pain

ArticleYear
Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.
    Cardiovascular drugs and therapy, 2009, Volume: 23, Issue:4

    Topics: Aged; Alprostadil; Cardiotonic Agents; Carnitine; Chronic Disease; Double-Blind Method; Drug Synergi

2009
Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate.
    Journal of strength and conditioning research, 2007, Volume: 21, Issue:1

    Topics: Adult; Analysis of Variance; Area Under Curve; Biomarkers; Blood Glucose; Carnitine; Cross-Over Stud

2007
Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort.
    International journal of sports medicine, 1996, Volume: 17, Issue:5

    Topics: Adult; Analysis of Variance; Carnitine; Creatine Kinase; Humans; Male; Muscle, Skeletal; Pain; Pain

1996
L-carnitine supplementation in patients with cystic acne on isotretinoin therapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 1999, Volume: 13, Issue:3

    Topics: Acne Vulgaris; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Carni

1999
L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress.
    American journal of physiology. Endocrinology and metabolism, 2002, Volume: 282, Issue:2

    Topics: Adult; Biomarkers; Carnitine; Cross-Over Studies; Cytosol; Double-Blind Method; Exercise; Free Radic

2002

Other Studies

5 other studies available for carnitine and Pain

ArticleYear
[Efficacy of levocarnitine for tyrosine kinase inhibitor-induced painful muscle cramps in patients with chronic myelogenous leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2016, Volume: 57, Issue:4

    Topics: Adult; Carnitine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscl

2016
Methylcrotonyl-CoA carboxylase (MCC) deficiency associated with severe muscle pain and physical disability in an adult.
    Journal of inherited metabolic disease, 2005, Volume: 28, Issue:6

    Topics: Adolescent; Biopsy; Carbon-Carbon Ligases; Carnitine; Diagnosis, Differential; Female; Humans; Metab

2005
Carnitine: a therapeutic option for childhood psoriatic onycho-pachydermo-periostitis (POPP).
    Clinical rheumatology, 2007, Volume: 26, Issue:1

    Topics: Adolescent; Arthritis, Psoriatic; Carnitine; Humans; Male; Onycholysis; Pain; Thumb; Toes; Vitamin B

2007
[Administration of Hylase in Bechterew's disease].
    Zeitschrift fur arztliche Fortbildung, 1975, Nov-01, Volume: 69, Issue:21

    Topics: Adult; Carnitine; Drug Synergism; Humans; Hyaluronoglucosaminidase; Injections, Intravenous; Male; P

1975
Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle.
    Journal of neurology, neurosurgery, and psychiatry, 1987, Volume: 50, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Asthenia; Carnitine; Chronic Disease; Electron Transport Complex IV;

1987